Connect Biopharma Holdings Ltd (CNTB) company profile
Close on Nov 17, 2026Market cap $36.45MP/E –Yield –
About Connect Biopharma
Pharmaceutical Preparations, SIC 2834
Connect Biopharma is a clinical-stage biotechnology company that develops antibody therapies for inflammatory respiratory diseases. The company focuses on developing its lead drug candidate, rademikibart, an antibody targeting interleukin-4 receptor alpha. Rademikibart is in clinical development for treating acute exacerbations of asthma and chronic obstructive pulmonary disease, as well as for chronic treatment of these pulmonary conditions and atopic dermatitis. Its potential end-users are patients who suffer from these respiratory and inflammatory skin disorders.
The company is based in San Diego, California. It does not own or operate manufacturing facilities, instead relying on third-party contract manufacturers for raw materials and supplies. Connect Biopharma partners with Simcere Pharmaceutical to develop and commercialize rademikibart in Greater China, while maintaining rights in other global markets. Clinical trials for its drug candidate have taken place across several countries, including the United States, Poland, Hungary, China, South Korea, Australia, and New Zealand.
Summary of the business section of Connect Biopharma's latest annual report, written by StockData.
Company profile
Company
- Legal name
- Connect Biopharma Holdings Ltd
- Headquarters
- San Diego, CA
- Address
- 3580 Carmel Mountain Road, Suite 200 92130
- Phone
- (858) 727-1040
- Website
- connectbiopharma.com
- Industry
- Pharmaceutical Preparations
- Incorporated in
- E9
- Fiscal year ends
- December 31
- Auditor
- CBIZ CPAs P.C, New York, NY
Stock & identifiers
- Ticker
- CNTB
- Exchange
- Nasdaq
- IPO date
- Mar 19, 2021
- Shares outstanding
- 63M, Jul 31, 2026
- Public float
- $40.40M, Jun 30, 2025
- Filer category
- Non-accelerated filer<br>Smaller reporting company<br>Emerging growth company
- SEC CIK
- 1835268
- CUSIP
- 207523101
- ISIN
- US2075231017
- FIGI
- BBG00ZGYNJ49
- Share class FIGI
- BBG00ZGYNJZ5
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Barry D. Quart | Chief Executive Officer, Director | 224,034 |
| Lisa Peraza | Senior Vice President, Finance | 45,189 |
| David Leslie Szekeres | President | 215,739 |
| Jean I. Liu | Director | 20,763 |
| Kleanthis Gabriel Xanthopoulos | Director | 91,554 |
| James Huang | Director | 13,310,000 |
| James A. Schoeneck | Director | – |
| Karen J. Wilson | Director | 10,000 |
IPO
From the final prospectus (Form 424B4) and the first day of trading
Offering
- Type
- Initial public offering
- Final prospectus filed
- Mar 19, 2021
- Offer price
- $17.00
- Securities offered
- 11,250,000
- Gross proceeds
- $191.25M
- Exchange
- Nasdaq
- First trading day
- Mar 19, 2021
- First-day close
- $18.49+8.8%
- Lock-up ends (est.)
- Sep 15, 2021
“PER ADS TOTAL Initial public offering price $ 17.00 $ 191,250,000 Underwriting discounts and commissions (1) $ 1.19 $ 13,387,500 Proceeds to Connect Biopharma Holdings Limited, before expenses $ 15.81 $ 177,862,500 (1) See “Underwriting” for additional information regarding underwriting compensation.”
Lock-up end is estimated as 180 days after the first trading day; the prospectus sets the actual terms.
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Mar 19, 2021 | IPO | Initial public offering priced (424B4 prospectus) |
| Mar 12, 2021 | Listing | Registration of securities on an exchange (Form 8-A) |
See a number that looks wrong?